
Mak Capital One LLC
About Mak Capital One LLC’s 13F portfolio
Mak Capital One LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Mak Capital One LLC reported $713.8M across 17 US-listed positions (). Its largest position is AGILYSYS INC (AGYS) at 17% of the reported book, and its ten biggest holdings make up 82% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: AGYS AGILYSYS INC | — — | 17% | 1.2M | $124.6M |
| 2 | NASDAQ: GGAL GRUPO FINANCIERO GALICIA S.A | — — | 10% | 1.5M | $74.3M |
| 3 | NASDAQ: ACHC ACADIA HEALTHCARE COMPANY IN | — — | 10% | 2.4M | $71.8M |
| 4 | NASDAQ: QURE UNIQURE NV | — — | 8.0% | 1.2M | $56.7M |
| 5 | NYSE: SKY CHAMPION HOMES INC | — — | 7.8% | 632K | $55.7M |
| 6 | NASDAQ: AUTL AUTOLUS THERAPEUTICS LTD | — — | 7.5% | 33.6M | $53.8M |
| 7 | NASDAQ: CLPT CLEARPOINT NEURO INC | — — | 5.9% | 2.4M | $42.4M |
| 8 | NYSE: SUPV GRUPO SUPERVIELLE S.A. | — — | 5.8% | 4.3M | $41.1M |
| 9 | NASDAQ: CAI CARIS LIFE SCIENCES INC | — — | 4.8% | 1.9M | $34.5M |
| 10 | NASDAQ: ANNX ANNEXON INC | — — | 4.7% | 5.9M | $33.5M |
| 11 | NASDAQ: LAB STANDARD BIOTOOLS INC | — — | 3.3% | 28.8M | $23.7M |
| 12 | NYSE American: LODE COMSTOCK INC | — — | 3.0% | 5.2M | $21.6M |
| 13 | NASDAQ: CYRX CRYOPORT INC | — — | 2.8% | 1.3M | $20.1M |
| 14 | NASDAQ: HNST HONEST CO INC | — — | 2.4% | 4.8M | $17.5M |
| 15 | NYSE: CVE CENOVUS ENERGY INC | — — | 2.3% | 537K | $16.2M |
| 16 | NASDAQ: PESI PERMA-FIX ENVIRONMENTAL SVCS | — — | 2.1% | 1.0M | $14.8M |
| 17 | NASDAQ: YTRA YATRA ONLINE INC | — — | 1.6% | 12.2M | $11.5M |
Showing the 17 largest positions reported in this 13F.
- Healthcare44%
- Technology17%
- Financial Services16%
- Consumer Cyclical9.4%
- Industrials4.9%
- Basic Materials3.0%
- Consumer Defensive2.4%
- Energy2.3%
- AddedGGALGRUPO FINANCIERO GALICIA S.A+4.0%$74.3M
- AddedQUREUNIQURE NV+179%$56.7M
- AddedCLPTCLEARPOINT NEURO INC+24.9%$42.4M
- NewCAICARIS LIFE SCIENCES INC—$34.5M
- AddedANNXANNEXON INC+24.1%$33.5M
- AddedLABSTANDARD BIOTOOLS INC+10.1%$23.7M
- AddedPESIPERMA-FIX ENVIRONMENTAL SVCS+12.4%$14.8M
- ReducedSKYCHAMPION HOMES INC−50.7%$55.7M
- ReducedLODECOMSTOCK INC−10.0%$21.6M
- ReducedCYRXCRYOPORT INC−10.3%$20.1M
- SoldFVRRFIVERR INTL LTD−100%—
- SoldPLXPROTALIX BIOTHERAPEUTICS INC−100%—
- SoldUDMYUDEMY INC−100%—
- SoldSGMOSANGAMO THERAPEUTICS INC−100%—
- SoldCOURCOURSERA INC−100%—
Reading Mak Capital One LLC’s 13F portfolio
Mak Capital One LLC’s $713.8M 13F book is spread across 17 reported positions and is highly concentrated — its ten largest positions alone are 82% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are AGYS, GGAL, ACHC, QURE and SKY, led by AGILYSYS INC (AGYS) at 17% of the portfolio. The heaviest sector exposure is Healthcare (44%), then Technology (17%).
What Mak Capital One LLC changed last quarter
Between 2026-03-31 and Q2 2026, Mak Capital One LLC was roughly balanced between buying and selling: it opened 1 new positions and added to 6 more, while trimming 3 and closing 5 outright. Against a 17-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was GRUPO FINANCIERO GALICIA S.A (GGAL), and its biggest reduction was CHAMPION HOMES INC (SKY).
What a 13F does and doesn’t reveal
A 13F captures only Mak Capital One LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Mak Capital One LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Mak Capital One LLC's profile on this page is built directly from those filings.
How current is the 13F data on Mak Capital One LLC's page?
It reflects Mak Capital One LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Mak Capital One LLC files its next quarterly report, this page refreshes automatically.
Can I see Mak Capital One LLC's complete list of holdings?
This page highlights Mak Capital One LLC's largest positions rather than all 17 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Mak Capital One LLC's filings.
Does a 13F show everything Mak Capital One LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Mak Capital One LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Mak Capital One LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

